Cannabidiol

Phase 2

Canopy Growth Corp (CGC)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Menstrual Discomfort

View Full Landscape

Drug Information

Target Indication

Menstrual Discomfort

Clinical Trial

NCT05679830

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA9/19/2019

Epidyolex

Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

CGC

Canopy Growth Corp

Medicinal Chemicals & Botanical Products•North America•NASDAQ

Related Pipeline

CHI-554Phase 2

Anxiety

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts